• Latest
  • Trending
  • All
  • News
  • BUSINESS
  • SCIENCE
  • LIFESTYLE
  • TECH
U.S. FDA Accepts Astellas’ New Drug Application for Fezolinetant

U.S. FDA Accepts Astellas’ New Drug Application for Fezolinetant

August 18, 2022
Can CBD Help Heat Things Up in The Bedroom? Vitality CBD Says So

Can CBD Help Heat Things Up in The Bedroom? Vitality CBD Says So

March 25, 2023
Air Fryer Frozen Shrimp | The Recipe Critic

Air Fryer Frozen Shrimp | The Recipe Critic

March 25, 2023
Self-Care Tips for Parents of a Child With Central Precocious Puberty

Self-Care Tips for Parents of a Child With Central Precocious Puberty

March 25, 2023
Their Division Received the Most WWII Medals of Honor in Europe. But They Considered Themselves ‘Grunts’

Their Division Received the Most WWII Medals of Honor in Europe. But They Considered Themselves ‘Grunts’

March 25, 2023
Photos of the Week: Ramadan begins; Day of Silence

Photos of the Week: Ramadan begins; Day of Silence

March 25, 2023
Bankrupt – JCPenney

Bankrupt – JCPenney

March 25, 2023
Keep Bitcoin mining in America

Keep Bitcoin mining in America

March 25, 2023
Gordon Moore, Intel co-founder and creator of Moore’s Law, has died

Gordon Moore, Intel co-founder and creator of Moore’s Law, has died

March 25, 2023
The 42 Best Amazon Deals Right Now: Blenders, Skincare, and More

The 42 Best Amazon Deals Right Now: Blenders, Skincare, and More

March 25, 2023
Benson Hill Announces Preliminary Unaudited 2022 Results and … – Business Wire

Chairman McCaul Opening Statement at Today’s Committee Markup … – House Foreign Affairs Committee

March 25, 2023
Should Soy Sauce Be Refrigerated?

Should Soy Sauce Be Refrigerated?

March 25, 2023
How to Get a DEEP DISCOUNT on Properties with Back Taxes

How to Get a DEEP DISCOUNT on Properties with Back Taxes

March 25, 2023
  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds
No Result
View All Result
No Result
View All Result
Home PRESS RELEASE

U.S. FDA Accepts Astellas’ New Drug Application for Fezolinetant

by Minnesota Digital News
August 18, 2022
in PRESS RELEASE
0
U.S. FDA Accepts Astellas’ New Drug Application for Fezolinetant
496
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter


If approved by the FDA, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause

TOKYO, Aug. 18, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2

The PDUFA target action date is February 22, 2023, following use of a priority review voucher (PRV). Astellas booked ¥13.1 billion of amortization of the intangible asset relating to PRV as R&D expense in the first quarter of fiscal year 2022.

“The FDA’s acceptance of our NDA for fezolinetant brings us one step closer to advancing care for women in the U.S. who experience VMS,” said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Development Therapeutic Areas, Astellas. “We look forward to the FDA’s review of our application, and the potential to offer a first-in-class nonhormonal treatment option to reduce the frequency and severity of moderate to severe VMS associated with menopause.”

The NDA is supported by results from the BRIGHT SKY™ program, which included three Phase 3 clinical trials that collectively enrolled over 2,800 women with VMS across the U.S., Canada and Europe. Results from the SKYLIGHT 1™ and SKYLIGHT 2™ pivotal trials characterize the efficacy and safety of fezolinetant for the treatment of moderate to severe VMS associated with menopause. Data from the SKYLIGHT 4™ safety study further characterizes the long-term safety profile of fezolinetant. Within the NDA, Astellas proposes a 45 mg daily dose, which is subject to the FDA’s review.

Fezolinetant is an investigational nonhormonal selective neurokinin 3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established.

The impact of this acceptance on Astellas’ financial results of the current fiscal year ending March 31, 2023, is expected to be minor.

About the BRIGHT SKY™ Phase 3 Program

The BRIGHT SKY pivotal trials, SKYLIGHT 1™ (NCT04003155) and SKYLIGHT 2™ (NCT04003142), enrolled over 1,000 women with moderate to severe VMS. The trials are double-blinded, placebo-controlled for the first 12 weeks followed by a 40-week treatment extension period. Women were enrolled at over 180 sites within the U.S., Canada and Europe. SKYLIGHT 4™ (NCT04003389) is a 52-week double-blinded, placebo-controlled study designed to investigate the long-term safety of fezolinetant. For SKYLIGHT 4, over 1,800 women with VMS were enrolled at over 180 sites within the U.S., Canada and Europe. 

About VMS Associated with Menopause

VMS, characterized by hot flashes (also called hot flushes) and/or night sweats, are common symptoms of menopause.1,2 In the U.S., about 60% to 80% of women experience these symptoms during or after the menopausal transition and, worldwide, more than half of women 40 to 64 years of age experience VMS.3,4,5,6 VMS can have a disruptive impact on women’s daily activities and overall quality of life.1

About Fezolinetant

Fezolinetant is an investigational oral, nonhormonal therapy in clinical development for the treatment of moderate to severe VMS associated with menopause. Fezolinetant works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron to moderate neuronal activity in the thermoregulatory center of the brain (the hypothalamus) to reduce the frequency and severity of moderate to severe VMS associated with menopause.7,8,9 The safety and efficacy of fezolinetant are under investigation and have not been established. There is no guarantee the agent will receive regulatory approval or become commercially available for the uses being investigated.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

References

1 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.

2 Jones RE, Lopez KH, eds. Human Reproductive Biology. 4th ed. Waltham, MA: Elsevier, 2014:120.

3 Makara-Studzinska MT, Krys-Noszczyk KM, Jakiel G. Epidemiology of the symptoms of menopause – an intercontinental review. Przegl Menopauzalny [Menopause Rev]. 2014;13:203-211.

4 Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96:1226-1235.

5 Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21:924-932.

6 Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008;11:32-43.

7 Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-905. 

8 Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27:382-92. 

9 Fraser GL, Hoveyda HR, Clarke IJ, Ramaswamy S, Plant TM, Rose C, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderate levels of ovarian hormones throughout the menstrual cycle. Endocrinology. 2015;156:4214-25. 

SOURCE Astellas Pharma Inc.



Source link

Share198Tweet124Share50
Minnesota Digital News

Minnesota Digital News

Saint Paul
◉
30°
Cloudy
7:05 am7:30 pm CDT
Feels like: 27°F
Wind: 4mph N
Humidity: 70%
Pressure: 29.77"Hg
UV index: 0
SunMonTueWed
39/19°F
41/19°F
36/19°F
36/23°F
Weather forecast Saint Paul, Minnesota ▸
Can CBD Help Heat Things Up in The Bedroom? Vitality CBD Says So
FASHION

Can CBD Help Heat Things Up in The Bedroom? Vitality CBD Says So

by Minnesota Digital News
March 25, 2023
Air Fryer Frozen Shrimp | The Recipe Critic
FOOD

Air Fryer Frozen Shrimp | The Recipe Critic

by Minnesota Digital News
March 25, 2023
Self-Care Tips for Parents of a Child With Central Precocious Puberty
HEALTH

Self-Care Tips for Parents of a Child With Central Precocious Puberty

by Minnesota Digital News
March 25, 2023
Their Division Received the Most WWII Medals of Honor in Europe. But They Considered Themselves ‘Grunts’
HISTORY

Their Division Received the Most WWII Medals of Honor in Europe. But They Considered Themselves ‘Grunts’

by Minnesota Digital News
March 25, 2023
Photos of the Week: Ramadan begins; Day of Silence
Religion

Photos of the Week: Ramadan begins; Day of Silence

by Minnesota Digital News
March 25, 2023
Bankrupt – JCPenney
Shopping

Bankrupt – JCPenney

by Minnesota Digital News
March 25, 2023
Keep Bitcoin mining in America
BUSINESS

Keep Bitcoin mining in America

by Minnesota Digital News
March 25, 2023
Gordon Moore, Intel co-founder and creator of Moore’s Law, has died
TECH

Gordon Moore, Intel co-founder and creator of Moore’s Law, has died

by Minnesota Digital News
March 25, 2023
The 42 Best Amazon Deals Right Now: Blenders, Skincare, and More
ENTERTAINMENT

The 42 Best Amazon Deals Right Now: Blenders, Skincare, and More

by Minnesota Digital News
March 25, 2023
Benson Hill Announces Preliminary Unaudited 2022 Results and … – Business Wire
PRESS RELEASE

Chairman McCaul Opening Statement at Today’s Committee Markup … – House Foreign Affairs Committee

by Minnesota Digital News
March 25, 2023
Should Soy Sauce Be Refrigerated?
LIFESTYLE

Should Soy Sauce Be Refrigerated?

by Minnesota Digital News
March 25, 2023
How to Get a DEEP DISCOUNT on Properties with Back Taxes
REAL ESTATE

How to Get a DEEP DISCOUNT on Properties with Back Taxes

by Minnesota Digital News
March 25, 2023
Zillow Now Accounts For Nearly Half of All Real Estate Web Traffic: Analysis
SCIENCE

Zillow Now Accounts For Nearly Half of All Real Estate Web Traffic: Analysis

by Minnesota Digital News
March 25, 2023
nubia Pad 3D is now available for pre-order
MOBILE

nubia Pad 3D is now available for pre-order

by Minnesota Digital News
March 25, 2023
Intel co-founder Gordon Moore has passed away
GADGET

Intel co-founder Gordon Moore has passed away

by Minnesota Digital News
March 25, 2023
Always remember us this way – Live cover from Starmaker Apps (4 years ago)
APPS

Always remember us this way – Live cover from Starmaker Apps (4 years ago)

by Minnesota Digital News
March 25, 2023
Locafy says prelim FY22 revenue nearly doubled
MARKET

Warning: TLSNY is at high risk of cutting its dividend

by Minnesota Digital News
March 25, 2023
Is the US Preparing for the “NATOization” of Bosnia?
ECONOMY

Your ‘Recycled’ Grocery Bag Might Not Have Been Recycled

by Minnesota Digital News
March 25, 2023
Nigerian Banks Not Directly Exposed to SVB Says Central Bank Governor – Africa Bitcoin News
CRYPTO

Nigerian Banks Not Directly Exposed to SVB Says Central Bank Governor – Africa Bitcoin News

by Minnesota Digital News
March 25, 2023
Minnesota Digital News

Copyright © 2022 Minnesota Digital News

Navigate Site

  • Disclaimer
  • Privacy Policy
  • Copyright Notice
  • Anti Spam Policy
  • Medical Disclaimer
  • DMCA Compliance
  • Terms and Conditions
  • Social Media Disclaimer
  • Amazon Affiliate disclaimer

Follow Us

No Result
View All Result
  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds

Copyright © 2022 Minnesota Digital News